Skip to main content
$363.80 -$13.38 (-3.5%)

04:00 PM EDT on 09/28/21


CAPS Rating: 4 out of 5

Current Price $363.80 Mkt Cap $35.1B
Open $376.92 P/E Ratio 0.00
Prev. Close $363.80 Div. (Yield) $0.00 (0.0%)
Daily Range $357.00 - $376.92 Volume 303,256
52-Wk Range $219.20 - $426.56 Avg. Daily Vol. 389,330


How do you think NASDAQ:BGNE will perform against the market?

Add Stock to CAPS Watchlist

All Players

44 Outperform
1 Underperform

All-Star Players

18 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:BGNE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

XMFInnovator (< 20)
Submitted July 09, 2018

BeiGene is a biotech company focused on becoming “the Genetech of China.” Its approach involves developing cancer immunotherapy drugs that are personalized for patients who can be characterized by their particular tumor subgroup.Its research platform… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!



Fools bullish on NASDAQ:BGNE are also bullish on:

Fools bearish on NASDAQ:BGNE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BGNE.


Member Avatar TMFjimhalley (30.24) Submitted: 6/21/2021 7:42:58 PM : Outperform Start Price: $319.66 NASDAQ:BGNE Score: +10.81

It has a strong pipeline led by two main drugs as well as the ability to use its Chinese connections to help other pharmaceutical companies in collaboration efforts.


Member Avatar CBK (51.58) Submitted: 7/1/2020 12:45:40 PM : Outperform Start Price: $191.33 NASDAQ:BGNE Score: +50.71

-China’s biotech industry is embarking on a renaissance. BeiGene is emerging as an important leader in this movement.
-The company’s late-stage pipeline is winning commercial approvals both in China and in the rest of the developed world.
-Tislelizumab won approval in China last year and generated $20 million in product revenue during its first month of sales.
-Brukinsa was approved by the FDA.
-Amgen struck a deal with them for 20 new drugs to develop and took a 20.5% stake in them.


Member Avatar Bigsef77 (69.73) Submitted: 1/15/2019 3:16:53 PM : Outperform Start Price: $168.98 NASDAQ:BGNE Score: +63.74

BeiGene drug gets 'breakthrough therapy' designation from FDA
Wallace Witkowski
,MarketWatch•January 14, 2019

U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.


Find the members with the highest scoring picks in BGNE.

Score Leader


portefeuille (98.60) Score: +1,160.96

The Score Leader is the player with the highest score across all their picks in BGNE.

Member Name Member
Call Time
Score Commentary
portefeuille 98.60 2/10/2016 5/31/2021 Outperform NS $26.13 +1,293.02% +132.06% +1,160.96 0 Comment
jeepdrew222 74.45 9/8/2016 Outperform 5Y $29.68 +1,126.40% +98.39% +1,028.01 0 Comment
portefeuille3 97.17 9/28/2016 Outperform 5Y $30.81 +1,081.42% +101.29% +980.13 0 Comment
SeriousK 28.98 11/29/2016 Outperform 5Y $31.07 +1,071.53% +96.68% +974.85 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 49.01 5/23/2017 Outperform 5Y $36.87 +887.24% +80.75% +806.49 0 Comment
portefeuille2 98.95 9/1/2017 Outperform 5Y $69.45 +424.11% +74.94% +349.17 0 Comment
sublimeinvestor 79.96 8/8/2017 Outperform 5Y $77.30 +370.89% +74.65% +296.24 0 Comment
Plasmidologist 89.54 8/8/2017 Outperform 5Y $77.49 +369.73% +74.63% +295.10 0 Comment
drnetops1958 27.47 5/9/2019 Outperform 5Y $122.27 +197.70% +52.06% +145.64 0 Comment
TMFSunFire 96.43 1/4/2019 Outperform 5Y $121.87 +198.69% +73.98% +124.70 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BGNE.